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a  b  s  t  r  a  c  t
Objectives:  Both  bone  and  brain  are frequent  sites  of  metastasis  in non-small  cell  lung  cancer  (NSCLC).
Conflicting  data  exist  whether  EGFR  mutant  (+)  patients  are  more  prone  to develop  brain  metastases  or
have  a better  outcome  with  brain  metastases  compared  to  EGFR/KRAS  wildtype  (WT)  or  KRAS+  patients.
For  bone  metastases  this  has  not  been  studied.
Methods:  In  this  retrospective  case-control  study  all EGFR+  (exons  19 and  21)  patients  diagnosed  at  two
pathology  departments  were  selected  (2004/2008  to 2012).  For  every  EGFR+  patient  a consecutive  KRAS+
and  WT  patient  with metastatic  NSCLC  (mNSCLC)  was  identified.  Patients  with  another  malignancy  within
2  years  of mNSCLC  diagnosis  were  excluded.  Data  regarding  age, gender,  performance  score,  histology,
treatment,  bone/brain  metastases  diagnosis,  skeletal  related  events  (SRE)  and  subsequent  survival  were
collected.
Results: 189  patients  were  included:  62  EGFR+,  65  KRAS+,  62  WT.  32%,  35%  and  40%,  respectively,  had
brain  metastases  (p =  0.645).  Mean  time  to  brain  metastases  was  20.8  [±12.0],  10.8  [±9.8],  16.4  [±10.2]
months  (EGFR+–KRAS+,  p =  0.020,  EGFR+–WT,  p  =  0.321).  Median  post  brain  metastases  survival  was  12.1
[5.0–19.1],  7.6  [1.2–14.0],  10.7  [1.5–19.8]  months  (p  =  0.674).  60%,  52%  and  50%  had  metastatic  bone
disease (p =  0.528).  Mean  time  to  development  of  metastatic  bone  disease  was 13.4  [±10.6],  23.3  [±19.4],
16.4  [±9.6]  months  (p = 0.201).  Median  post metastatic  bone  disease  survival  was  15.0  [10.6–20.3],  9.0
[5.2–12.9],  3.2  [0.0–6.9]  months  (p  =  0.010).  Time  to  1st  SRE  was  not  significantly  different.
Conclusions:  Incidence  of brain  and  bone  metastases  was  not  different  between  EGFR+,  KRAS+  and  WT
patients.  Post  brain  metastases  survival,  time  from  mNSCLC  diagnosis  to metastatic  bone  disease  and  1st
SRE did  not  differ  either.  Post  metastatic  bone  disease  survival  was  significantly  longer  in  EGFR+  patients.
Although  prevention  of  SRE’s  is  important  for all patients,  the  latter  finding  calls for  a separate  study  for
SRE preventing  agents  in  EGFR+  patients.∗ Corresponding author. Tel.: +31 0433871318; fax: +31 0433875051.
E-mail address: lizza.hendriks@mumc.nl (L.E.L. Hendriks).
169-5002/$ – see front matter © 2014 Elsevier Ireland Ltd. All rights reserved.
ttp://dx.doi.org/10.1016/j.lungcan.2014.01.006© 2014  Elsevier  Ireland  Ltd.  All  rights  reserved.
1. Introduction
Metastatic non-small cell lung cancer (mNSCLC) patients with
activating epidermal growth factor receptor mutations (EGFR+)
have, compared to KRAS mutated (KRAS+) or EGFR/KRAS wildtype
(WT) patients, a longer progression free survival (PFS) and overall






















































compared to KRAS+ and WT patients: 26.7 [20.4–32.9]; 11.0
[6.8–15.1] and 11.5 [7.6–15.3] months respectively (HR 1.379
[1.135–1.677], p < 0.0001, Fig. 1). Within the EGFR+ group, median
OS was significantly longer for exon 19 than in exon 21 mutatedL.E.L. Hendriks et al. / L
TKI) [1–3]. Differences in tumor biology may  also reflect metastatic
attern. Similar to patients with (EGFR/erB family member) HER2
ositive breast cancer [4], the incidence of brain metastases may
e higher in EGFR+ patients as compared to EGFR− patients[5–9].
ne explanation is the inability of currently available EGFR-TKI to
ross the intact blood-brain barrier at recommended doses [10]. In
he above mentioned studies only patients with brain metastases
ere enrolled [5,7,9] and/or mutation status was not known for all
ncluded patients [6,8,9]. Thus, the question whether the time to
evelopment of brain metastases and outcome is different between
GFR+, KRAS+ or WT  patients could not be answered. Next to brain,
one is a frequent site of metastasis in NSCLC exerting a negative
mpact on quality of life [11–13]. Brain metastases have also a nega-
ive impact on survival [14]. Different metastatic patterns may  have
mplications for diagnostic strategies (e.g. screening) and treatment
ecisions (e.g. prophylactic treatment).
In this retrospective case-control study we compared EGFR+
o KRAS+ and WT  mNSCLC patients to determine whether EGFR+
atients are more prone to develop brain metastases and/or
etastatic bone disease, and whether they have a different survival
ollowing the detection of these metastases.
. Materials and methods
This study was designed as a retrospective case-control study,
sing a prospectively collected database.
Patient selection: All EGFR+ patients who were diagnosed at
he pathology departments of two university hospitals (MUMC+
nd VUMC) were selected. For every EGFR+ patient the consec-
tive KRAS+ and WT  NSCLC patient was selected. The MUMC+
atabase covers the period 01-10-2008 to 01-08-2012 and the
UMC database 01-11-2004 to 01-01-2012. The MUMC+  pathology
epartment performs mutation analysis for the MUMC+  (both gen-
ral and referral hospital) and four surrounding general hospitals.
rom the VUMC database only patients who underwent treatment
t VUMC (mainly referral hospital) were selected in order to obtain
ufficient follow-up data.
Inclusion criteria: mNSCLC and known mutation status (activat-
ng EGFR+: exon 19 deletion or exon 21 mutation, KRAS+ or WT
defined as: no EGFR or KRAS mutation)).
Exclusion criteria:  exon 18 or 20 EGFR mutation, other active
alignancy within 2 years of diagnosis of mNSCLC, mixed histology,
ML4-ALK translocation positive (when testing was performed) or
o follow-up data available (at least one visit after diagnosis of
NSCLC required).
The in- and outpatient medical records of all patients were
etrieved and the following data were collected: age at diagno-
is of mNSCLC; gender; smoking status; date of first diagnosis
SCLC and of mNSCLC; histology; treatment; development, num-
er, symptoms and treatment of brain metastases; development,
nd treatment of metastatic bone disease, skeletal related event
SRE) and time of death. Last date of follow-up was August 2013.
Medical ethical committee approval was not obtained in accor-
ance with local regulations, as it is a retrospective study with no
nterventions.
.1. Mutation analysis
Mutation analysis for EGFR (exons 18–21) and KRAS (exons 2–3)
as performed as part of standard of care with high resolution
elting as pre-screening followed by Sanger sequencing to confirm
enotype [15]..2. Statistical analysis
Statistics were performed using SPSS (IBM statistics, version
0). Descriptive statistics of demographic and clinical variablesncer 84 (2014) 86–91 87
were obtained. Categorical variables were compared using chi-
square tests, continuous variables were compared using ANOVA.
For patients without metastatic bone disease or brain metastases
at first diagnosis of mNSCLC, time to diagnosis of these metastases
was calculated from diagnosis of mNSCLC and was  expressed as
mean with standard deviation (SD). Means were compared using
ANOVA with, if statistically significant, post hoc Student’s t-tests
for pair wise comparisons. OS was defined as time from diagno-
sis of mNSCLC to death and post metastatic bone disease and post
brain metastases survival was  calculated from diagnosis of these
metastases to death (patients without event were censored at last
visit). Both were estimated using the Kaplan–Meier method. Sur-
vival curves were compared using the log-rank test. To estimate
the hazard ratio (HR), Cox regression analysis was used.
3. Results
3.1. Patient characteristics
Respectively 59/603 (9.8%) and 26/346 (7.5%) NSCLC patients
included in the MUMC+  and VUMC database carried an EGFR muta-
tion. These 85 EGFR+ patients were paired with the consecutive
KRAS+ and WT  patients. The medical records of these 255 patients
were analyzed. 3 EGFR+ patients had an exon 18 mutation and 8
had an exon 20 mutation; these patients were excluded together
with the consecutive KRAS+ and WT  patient. In addition, 33 patients
were excluded because of: no metastatic disease (N = 13), another
malignancy diagnosed within 2 years of mNSCLC diagnosis (N = 10),
no follow up data (N = 8) or ALK translocation (N = 2). Finally, 189
patients were included in the analysis: 62 EGFR+, 65 KRAS+ and 62
EGFR/KRAS WT  (WT). Patient characteristics are shown in Table 1.
Most EGFR+ patients (58/62 (93.5%)) received an EGFR-TKI during
the course of their disease, 41/58 (70.7%) as first line treatment.
Of the 62 EGFR+ patients, 41 had exon 19 deletions and 21 had
exon 21 mutations (of which one combined with an exon 19 dele-
tion).
3.2. Overall survival
Median OS [95% CI] was significantly longer for EGFR+ patientsFig. 1. Overall survival for EGFR+, KRAS+ arid WT patients.









Female N (%) 46 (74.2) 38 (58.5) 26 (41.9) 0.001
Mean  age, years (range) 60.7 (29.3–90.7) 61.0 (35.1–83.3) 63.0 (39.6–81.8) 0.532
Never smoker N (%) 25 (40.3) 2 (3.1) 9 (14.5) <0.001
WHO  PS 0–2 N (%) 59 (95.2) 62 (95.4) 60 (96.8) 0.164
Adenocarcinoma N (%) 57 (91.9) 53 (81.5) 52 (83.9) 0.217
Stage  IV disease at first diagnosis N (%) 54 (87.1) 49 (75.4) 61 (83.9) 0.205
PET-CT at first diagnosis of metastatic disease N (%)a 38 (61.3) 46 (70.8) 48 (77.4) 0.232
Mutation analysis performed at first diagnosis of
metastatic disease N (%)
42 (67.7) 45 (69.2) 47 (75.8) 0.480
1st  line treatment N (%)
None 3 (4.8) 8 (12.3) 11 (17.7) 0.080
Chemotherapy 18 (29.0) 55 (84.6) 46 (74.2) <0.001
EGFR-TKI 41 (66.2) 2 (3.1) 5 (8.1) <0.001





















GFR, epidermal growth factor receptor; WHO  PS, World Health Organisation Perfo
a Except for one wildtype patient and for four patients missing data: all other pat
atients: 29.8 [22.1–37.5] and 15.5 [9.4–22.6] months, respectively
HR 1.550 [1.122–2.141], p = 0.006).
.3. Brain metastases
Incidence of brain metastases was not different between the
 groups: 20/62 (32.3%) EGFR+, 23/65 (35.4%) KRAS+ and 25/62
40.3%) WT  patients had brain metastases (p = 0.645). At diagno-
is of mNSCLC brain metastases were present in 5/20 (25.0%), 9/23
39.1%) and 13/25 (52.0%) patients (p = 0.184). Mean time [SD] to
iagnosis of brain metastases for patients without brain metas-
ases at initial diagnosis of mNSCLC was 20.8 [±12.0]; 10.8 [±9.8]
nd 16.4 [±10.2] months, respectively. EGFR+ patients had a signif-
cantly longer time to development of brain metastases than KRAS+
p = 0.020) but not compared to WT  patients (p = 0.321). No signif-
cant difference in median [95% CI] post brain metastases survival
as observed: 12.1 [5.0–19.1]; 7.6 [1.2–14.0] and 10.7 [1.5–19.8]
onths (HR 1.119 [0.801–1.565], p = 0.674, Table 2, Fig. 2).
All 15 EGFR+ patients who developed brain metastases after ini-
ial diagnosis of mNSCLC were treated with an EGFR-TKI during
he course of their disease (9/15 (60%) first line, 12/15 (80%) before
evelopment of brain metastases). Mean time [SD] to development
Fig. 2. survival post brain metastases for EGFR+, KRAS+ and WT patients.ce Score; TKI, tyrosine kinase inhibitor.
Ct-thorax/upper abdomen.
of brain metastases was  not significantly different between EGFR+
patients who were in first line treated with an EGFR-TKI versus
patients who  received it in a later line (21.3 [±12.9] months versus
18.8 [±9.2] months p = 0.760) nor was there a significant difference
in time to brain metastases for patients who received an EGFR-
TKI or only chemotherapy before development of brain metastases
(21.4 [±12.4] months versus 17.3 [±12.5] months, p = 0.675). In the
latter group (N = 3) EGFR-TKI treatment was  started after diagnosis
of brain metastases. Median survival [95% CI] post brain metastases
was not significantly different between patients receiving an EGFR-
TKI before or after development of brain metastases (6.8 [0.0–18.9]
months compared to 11.0 [9.1–12.8] months) (p = 0.808). In addi-
tion no difference in OS was  observed (37.3 [16.5–58.1] months and
31.6 [12.2–51.1] months, respectively, p = 0.861).
3.4. Metastatic bone disease
Incidence of bone metastases was  also not different between
EGFR, KRAS+ and WT  patients: 37/62 (59.7%) EGFR+, 34/65 (52.3%)
KRAS+ and 31/62 (50.0%) WT  patients were diagnosed with or
developed metastatic bone disease during the course of their dis-
ease (p = 0.528). Of these 20/37 (54.1%), 26/34 (76.5%) and 18/31
(58.1%), respectively, had metastatic bone disease at diagnosis of
mNSCLC (p = 0.121). Mean time [SD] to first diagnosis of metastatic
bone disease for patients without metastatic bone disease at ini-
tial diagnosis of mNSCLC was  respectively 13.4 [±10.6]; 23.3
[±19.4] and 16.4 [±9.6] months for EGFR+, KRAS+ and WT patients,
(p = 0.201). No difference in SRE’s was observed: 19/37 (51.4%),
22/34 (64.7%) and 15/31 (48.4%), respectively (p = 0.361). Also,
time to first SRE was  equal (p = 0.213). However, post metastatic
bone disease survival was significantly longer in the EGFR+ group:
median [95% CI] of 15.5 [10.6–20.3] months compared to 9.0
[5.2–12.9] months for KRAS+ and 3.2 [0–6.9] months for WT
patients. (EGFR+–KRAS+, p = 0.049, EGFR+–WT, p = 0.004), Table 2,
Fig. 3). Mean time [SD] to development of metastatic bone disease
was longer, however not significant, for EGFR+ patients first line
treated with EGFR-TKI (15.9 [±11.1] months) compared to those
treated initially with chemotherapy (7.3 [±6.7] months) (p = 0.380).
4. Discussion
It is well known that patients presenting with an activating EGFR
mutation have a better prognosis than KRAS+ or WT patients [1–3].
Although it is frequently suggested that EGFR+ patients, like HER2
positive breast cancer patients, are more prone to develop brain
metastases during the course of their disease [5–9], this could not
L.E.L. Hendriks et al. / Lung Cancer 84 (2014) 86–91 89
Table  2









Imaging at 1st diagnosis of mNSCLC N (%)
MRI 15 (24.2) 19 (29.2) 18 (29.0) 0.417
CT  20 (32.3) 25 (38.5) 28 (45.2)
Nonec 25 (40.3) 19 (29.2) 16 (25.8)
Missing 2 (3.2) 2 (3.1) 0 (0.0)
Brain  mets N (%)
Yes 20 (32.3) 23 (35.4) 25 (40.3) 0.645
At  diagnosis 5 (25.0) 9 (39.1) 13 (52.0) 0.184
During follow up 15 (75.0) 14 (60.9) 12 (48.0)
No  42 (67.7) 42 (64.6) 37 (59.7)
Time to brain mets months [SD] 20.8 [±12.0] 10.8[±9.8] 16.4 [±10.2] EGFR/KRAS 0.020,
EGFR/WT 0.321
EGFR-TKI before brain mets N (%)- (first line) 15 (100.0)–12 (80) 1 (7.1) 4 (33.3) < 0.001
Symptomatic N (%) 16 (80.0) 17 (73.9) 24 (96.0) 0.097
WBRT  N (%) 12 (60.0) 11 (47.8) 20 (80.0) 0.028
SRS  N (%) 2 (10.0) 8 (34.8) 6 (24.0) 0.161
Surgery N (%) 0 (0.0) 3 (13.0) 1 (4.0) 0.260
Post  brain mets survival months [95% CI] 12.1 [5.0–19.1] 7.6 [1.2–14.0] 10.7 [1.5–19.8] 0.674
Bone  metastases
Imaging at 1st diagnosis of mNSCLC N (%)
PET-CT 38 (61.3) 46 (70.8) 48 (77.4) 0.232
CTa 17 (27.4) 13 (20.0) 11 (17.7)
Bone scintigraphyb 5 (8.1) 4 (6.2) 2 (3.3)
Missing 2 (3.2) 2 (3.0) 1 (1.6)
Bone  mets N (%)
Yes 37 (59.7) 34 (52.3) 31 (50.0) 0.528
At  diagnosis 20 (54.1) 26 (76.5) 18 (58.1) 0.121
During follow up 17 (45.9) 8 (23.5) 13 (41.9)
No  25 (40.3) 31 (47.7) 31 (50.0)
Time to bone mets months [SD] 13.4 [±10.6] 23.3 [±19.4] 16.4 [±9.6] 0.201
SRE+  N (%) 19 (51.4) 22 (64.7) 15 (48.4) 0.361
Time  to 1st SRE months [95% CI] 12.9 [5.0–20.7] 7.3 [0.0–14.9] 3.5 [0–7.7] 0.213
Post  bone mets survival months [95% CI] 15.5 [10.6–20.3] 9.0 [5.2–12.9] 3.2 [0–6.9] EGFR/KRAS 0.049
EGFR/WT 0.004
EGFR: epidermal growth factor receptor; 95% CI = 95% confidence interval; SD = standard deviation; SRE = skeletal related event; EGFR-TKI = epidermal growth factor receptor;
WBRT  = whole brain radiotherapy; SRS = stereotactic radiosurgery.
a Ct-thorax/upper abdomen.
b When both PET-CT and bone scintigraphy were performed, patients were scored for “
c Only low dose CT brain during PET-CT was scored as “none”.Fig. 3. Survival post bone metastases for EGFR+, KRAS+ and WT patients.PET-CT”.
be confirmed in our retrospective case-control study. To our knowl-
edge, this is the first case control study of EGFR+, KRAS+ and WT
patients with follow-up from first diagnosis of mNSCLC to evalu-
ate incidence of brain and bone metastases and survival thereafter.
Although this was a retrospective study, bias regarding staging
and treatment has been minimized by not selecting exclusively
patients with brain metastases at diagnosis, but including all con-
secutive patients with an activating EGFR mutation and comparing
the pattern of metastasis with consecutive KRAS+ and EGFR/KRAS
WT patients. In the literature, one study is available that investi-
gated the prevalence of metastases at first diagnosis of mNSCLC
however without follow-up data [16]. In this study (209 consecu-
tive nonsquamous mNSCLC patients, 39 EGFR+, 49 KRAS+, 41 ALK+
and 80 triple negative) comparable results were obtained. The per-
centage of bone and brain metastases was  not significantly different
between EGFR+, KRAS+, ALK+ and triple negative patients at initial
diagnosis of mNSCLC [4].
In our study time to development of brain metastases was  sig-
nificantly longer in EGFR+ patients compared to KRAS+ patients,
but survival post brain metastases was not significantly different.
Although different treatments (EGFR-TKI versus chemotherapy)
might influence development of and survival after brain metas-
tases in EGFR+ patients in our study time to development of
brain metastases was not significantly different for EGFR+ patients
treated with EGFR-TKI compared to chemotherapy. However, with
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iagnosis of mNSCLC, numbers are too small to draw firm conclu-
ions. In contrast, in a retrospective study of Heon et al., including
55 EGFR+ patients, time to central nervous system progression
as significantly longer in the EGFR-TKI than in the chemother-
py group (median of 56 versus 31.6 months) [17]. In this study
NS progression was defined not only as newly diagnosed brain
etastases, but also as growth of pre-existing metastases. Brain
etastases in EGFR+ patients respond to treatment with EGFR-TKIs
5,10,18–22] and radiation therapy [22,23], with median survival
ost brain metastases of 12–19 months [5,9,20,22]. Little is known
f post brain metastases survival in EGFR+ patients treated with
GFR-TKI who develop brain metastases. In two  retrospective
tudies (NY= 100 and N = 155), median survival after diagnosis of
rain metastases was 5.5 [24] and 5.9 months [17]. Although not
ignificant, in our study survival after diagnosis of brain metastases
as shorter when a patient was on EGFR-TKI treatment compared
o starting EGFR-TKI treatment after diagnosis of brain metastases
6.8 vs 11.0 months).
More aggressive treatment of EGFR+ patients developing brain
etastases while on EGFR-TKI treatment might prolong post
rain metastases survival. For example, treatment with irreversible
GFR-TKIs or pulse therapy EGFR-TKI has been studied [25–27]. In a
hase I trial with afatinib, a NSCLC patient developed brain metas-
ases during treatment with afatinib 10 mg  once daily, but had a 10
onth lasting intracranial response on afatinib 40 mg  once daily
27]. In another study, 6/9 patients with EGFR mutant lung can-
er who developed brain metastases during treatment with regular
oses of EGFR-TKI had a partial response to pulse therapy erlotinib
median of 1500 mg  weekly), another 2 had stable disease. Median
ime to central nervous system (CNS) progression was 2.8 months
range 0.8–14.5)[26]. Another option is radiotherapy and contin-
ation of EGFR-TKI, especially when the brain is the only site of
rogressive disease [28,29]. In one study, CNS response rate and
isease control rate were 41% and 76%, respectively. Median OS
as 408 days [28]. In another study, PFS was 1.7–11.1 months, OS
as not mentioned [29].
Our study did also not show a different incidence and time to
evelopment of metastatic bone disease between EGFR+, KRAS+
nd WT  patients. Survival post metastatic bone disease was signif-
cantly longer in the EGFR+ group, but incidence of first SRE and
ime to first SRE was not different. Based on these results, it seems
hat EGFR+ patients have a longer survival with SREs. Prevention
f metastatic bone disease and subsequent development of SREs
for example with bisphosphonates or denosumab) is important
or all patients, but may  be especially important in this subgroup
f patients due to a longer survival with metastatic bone disease
nd the higher change of developing a SRE. This calls for a separate
tudy of the effects of SRE preventing agents in EGFR+ patients.
trengths of the presented study include its multicenter character,
he prospectively collected database and the case-control design.
imitations include its retrospective nature and the small number
f patients with brain or bone metastases. As not all EGFR muta-
ions confer the same sensitivity to TKIs, only patients with exons
9 and 21 mutations were included. Some patients only received
est supportive care, but results did not change when we performed
 subgroup analysis excluding these patients (data not shown).
inally, as current practice is not to screen for metastatic bone dis-
ase or brain metastases in mNSCLC, in our series patients did not
ndergo standard imaging at first diagnosis of metastasized dis-
ase or during follow-up, leading to a possible underdiagnosis of
etastatic bone disease and brain metastases. Since the lack of
rain and/or bone imaging at first diagnosis of mNSCLC was similar
or the three groups, bias is less likely. To determine whether this
nfluenced our data at first diagnosis of mNSCLC, we reanalyzed the
ata excluding patients who had no brain or bone imaging at first
iagnosis of mNSCLC. Results were similar (data not shown).
[
ncer 84 (2014) 86–91
5. Conclusion
Incidence of metastatic bone disease and brain metastases was
not different between EGFR+, KRAS+ and WT  patients. Furthermore,
survival post metastatic bone disease was significantly longer in
the EGFR+ group, which stresses the impact of bone management
especially in these patients and probably warrant more intense
screening for metastatic bone disease.
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